Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern

Journal of Thoracic Oncology

Volumn 11, Issue 12, 2016, Pages 2141-2149

  Masai, Kyohei ^a,c   Tsuta, Koji ^b   Motoi, Noriko ^a   Shiraishi, Kouya ^a   Furuta, Koh ^a   Suzuki, Shigeki ^a   Asakura, Keisuke ^a   Nakagawa, Kazuo ^a   Sakurai, Hiroyuki ^a   Watanabe, Shun Ichi ^a   Hiraoka, Nobuyoshi ^a   Asamura, Hisao ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; EGFR; IPF; KRAS; Pulmonary fibrosis; UIP

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CONTROLLED STUDY; EGFR GENE; FEMALE; GENDER; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; ONCOGENE K RAS; ONSET AGE; RETROSPECTIVE STUDY; SEGMENTECTOMY; SMOKING; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME; WEDGE RESECTION; ADENOCARCINOMA; GENETICS; INTERSTITIAL LUNG DISEASE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85010775274     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.07.034     Document Type: Article

References (50)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
4. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963-967.
5. Callahan WP Jr, Sutherland JC, Fulton JK, et al. Acute diffuse interstitial fibrosis of the lungs. AMA Arch Intern Med. 1952;90:468-482.
6. Spain DM. The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc. 1957;76:559-566.
7. Meyer EC, Liebow AA. Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer. 1965;18:322-351.
8. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980;35:496-499.
9. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest. 1995;108:1272-1277.
10. Lee HJ, Im JG, Ahn JM, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings. J Comput Assist Tomogr. 1996;20:979-982.
11. Nagai A, Chiyotani A, Nakadate T, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med. 1992;167:231-237.
12. Fujita J, Yamadori I, Namihira H, et al. Increased intensity of lung infiltrates at the side of lung cancer in patients with lung cancer associated with pulmonary fibrosis. Lung Cancer. 1999;26:169-174.
13. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5-8.
14. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125:1321-1327.
15. Kishi K, Homma S, Kurosaki A, et al. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 2006;30:95-99.
16. Sakai S, Ono M, Nishio T, et al. Lung cancer associated with diffuse pulmonary fibrosis: CT-pathologic correlation. J Thorac Imaging. 2003;18:67-71.
17. Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int. 1999;49:1060-1066.
18. Ohtsuka Y, Ukita H, Masaki Y, et al. A prospective study of lung cancer in cases of idiopathic interstitial pneumonia (IIPS). Nihon Kyobu Shikkan Gakkai Zasshi. 1991;29:560-565.
19. Leslie HS, Mary KG, Christian W. TNM Classification of Malignant Tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.
20. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
21. Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res. 2008;14:4751-4757.
22. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35:1226-1234.
23. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol. 2011;6:1677-1686.
24. Stack BHR, Grand IWB, Irvine WJ, et al. Idiopathic diffuse interstitial lung disease. Am Rev Respir Dis. 1965;92:939-948.
25. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002;77:763-770.
26. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17:1216-1219.
27. Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995;45:925-932.
28. Kawasaki H, Nagai K, Yokose T, et al. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2001;76:53-57.
29. Lantuejoul S, Colby TV, Ferretti GR, et al. Adenocarcinoma of the lung mimicking inflammatory lung disease with honeycombing. Eur Respir J. 2004;24:502-505.
30. Sato T, Watanabe A, Kondo H, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149:64-69.
31. Ichinokawa H, Ishii G, Nagai K, et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol. 2013;44:2636-2642.
32. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371-376.
33. Kim V, Oros M, Durra H, et al. Chronic bronchitis and current smoking are associated with more goblet cells in moderate to severe COPD and smokers without airflow obstruction. PLoS One. 2015;10.
34. Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161:1016-1021.
35. Haswell LE, Hewitt K, Thorne D, et al. Cigarette smoke total particulate matter increases mucous secreting cell numbers in vitro: a potential model of goblet cell hyperplasia. Toxicol In Vitro. 2010;24:981-987.
36. Geles A, Gruber-Moesenbacher U, Quehenberger F, et al. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch. 2015;467:675-686.
37. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97-102.
38. Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer. 1996;32:512-517.
39. Saad RS, Liu YL, Han H, et al. Prognostic significance of thyroid transcription factor-1 expression in both earlystage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35:3-7.
40. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319-325.
41. Tsuta K, Ishii G, Nitadori J, et al. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol. 2006;209:78-87.
42. Gupta RK, Kaestner KH. HNF-4alpha: from MODY to lateonset type 2 diabetes. Trends Mol Med. 2004;10:521-524.
43. Sugano M, Nagasaka T, Sasaki E, et al. HNF4a as a marker for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol. 2013;37:211-218.
44. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29:633-639.
45. Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Lung Cancer. 2014;84:281-288.
46. Park WY, Kim MH, Shin DH, et al. Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin. Mod Pathol. 2012;25:1265-1274.
47. Kadota K, Yeh YC, D'Angelo SP, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014;38:1118-1127.
48. Inoue A, Saijo S, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
49. Kakegawa S, Shimizu K, Sugano M, et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 2011;117:4257-4266.
50. Martin P, Leighl NB, Tsao MS, et al. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol. 2013;8:530-542.